Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Topline symbols : Pfe save search
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
Published: 2023-12-01 (Crawled : 22:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -4.92%
H: 1.48%
C: -0.21%
obesity topline results
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Published: 2023-10-26 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -0.39%
H: 2.48%
C: 1.8%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
BNTX | News | $88.53 0.59% 0.59% 360K
|
Health Technology
|
| O: 0.99%
H: 1.81%
C: 0.47%
covid-19 vaccine positive influenza topline program
Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
Published: 2022-10-04 (Crawled : 11:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: 0.25%
H: 1.33%
C: 0.47%
topline trial positive results
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
Published: 2022-03-29 (Crawled : 01:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
trial potential positive results topline license phase 3 ulcerative colitis
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
Published: 2022-03-30 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: 0.87%
H: 0.98%
C: -1.43%
trial potential positive results topline license phase 3 ulcerative colitis
Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential
Published: 2022-03-29 (Crawled : 11:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
trial potential positive results phase 3 topline ulcerative colitis
Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients
Published: 2022-03-23 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -1.94%
H: 0.0%
C: 0.0%
trial positive results phase 3 topline ulcerative colitis
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Published: 2022-02-14 (Crawled : 12:30) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -1.89%
H: 1.36%
C: -0.04%
BHVN | News 0 d | $39.61 3.34% 0.0% 2.1M
|
Health Technology
|
| O: 0.27%
H: 2.86%
C: 1.95%
treatment trial migraine china topline results positive results topline
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
Published: 2022-01-12 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 0.0%
H: 0.0%
C: 0.0%
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -0.77%
H: 1.46%
C: 0.55%
phase 3 topline order
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released
Published: 2021-09-29 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: 0.42%
H: 1.09%
C: 0.72%
positive results vaccine phase 3 topline order
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
Published: 2021-08-30 (Crawled : 11:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -2.47%
H: 2.08%
C: 1.21%
positive results dermatitis phase 3 trial topline atopic dermatitis
Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata
Published: 2021-08-04 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -0.72%
H: 0.99%
C: -0.35%
phase 2 positive results phase 2b trial topline
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
Published: 2021-04-01 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: 0.19%
H: 0.41%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.22%
H: 0.51%
C: 0.02%
BNTX | News | $88.53 0.59% 0.59% 360K
|
Health Technology
|
| O: 1.21%
H: 3.23%
C: 3.04%
covid topline vaccine
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
Published: 2021-03-31 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: 0.11%
H: 0.77%
C: 0.22%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.59%
H: 0.36%
C: 0.12%
BNTX | News | $88.53 0.59% 0.59% 360K
|
Health Technology
|
| O: 4.81%
H: 1.4%
C: -0.25%
covid positive results topline vaccine covid-19
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.